InMed Pharmaceuticals (INM) said Tuesday that its INM-901 small molecule drug candidate for Alzheimer's disease reduced several plasma and brain markers of neuroinflammation in the trial.
The company said the study showed that INM-901 treated groups demonstrated a dose-dependent and statistically significant reduction in plasma pro-inflammatory cytokines and neurofilament light chain in the plasma for the high-dose treated group.
InMed also said the trial demonstrated a reduction of several key neuroinflammatory genes in the brain.
Shares of the company were up 43% in recent Tuesday premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。